ArticleLancet (London, England)2025

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial.

Armin Ghobadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.